The Congress did not show any error in the trial court’s conclusion that Center did not improperly seize the Congress’ corporate opportunity by running pharmaceutical symposia for the Center’s own benefit.  Substantial evidence supported the trial court’s factual findings that the Congress was not interested in drugs but rather was devoted solely to reconstructive joint surgery.  That the Center wrongly used some Congress resources to promote and hold the pharmaceutical symposia may have shown some other type of wrong, but not the seizure of the Congress’ corporate opportunity.